Plasma-Präkallikrein

M. J. Gallimore

doi:10.1055/s-0038-1660549

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 1987; 07(06): 166-171
DOI: 10.1055/s-0038-1660549

Originalarbeit

Schattauer GmbH

Plasma-Präkallikrein

M. J. Gallimore

¹Channel Diagnostics, Walmer, Kent, England

› Institutsangaben

Abstract

Zusammenfassung

Einfache Untersuchungsmethoden für die Bestimmung der Spiegel des Plasma-Präkallikreins und anderer Komponenten der plasmatischen Abwehrsysteme sind jetzt verfügbar. Obwohl diese Tests bisher nicht voll in der Klinik verwendet wurden, so erhielt man doch eine Menge nützlicher Informationen mit Hilfe dieser Tests. Zahlreiche Laboratorien in Europa verwenden bereits diese Tests, um Patienten während Intensivbetreuung zu beobachten, und verwenden die Ergebnisse für die Entwicklung neuer Therapien. Weitere Zustände, in denen die Analyse der Komponenten dieser Systeme von Vorteil sein könnten, schließen die Organtransplantation, Lebererkrankungen, Nierenerkrankungen, die rheumatoide Arthritis, allergische Erkrankungen, Thrombosen, Hypertonie und koronare Herzerkrankung ein.

Volltext

Referenzen

LITERATUR
1 Aasen A O. The proenzyme functional inhibition index. A new parameter for evaluation of the severely injured and septic patient. Acta Chir Scand 1985; Suppl 522: 211-9.
2 Aasen A O, Smith-Erichsen N, Gallimore M J, Amundsen E. Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock. Adv Shock Res 1980; 04: 1-10.
3 Aasen A O, Kierulf P, Ruud T E, Godai H C, Aune S. Studies on pathological proteolysis in patients with acute pancreatitis. A preliminary report. Acta Chir Scand 1982; Suppl 509: 83-8.
4 Amundsen E, Gallimore M J, Aasen A O, Larsbraaten M, Lyngaas K. Activation of human plasma prekallikrein : influence of activators, activation time and temperature and inhibitors. Thromb Res 1978; 13: 625-36.
5 Amundsen E, Aasen A O, Gallimore M J, Larsbraaten M, Lyngaas K, Engesett A. Plasma prekallikrein activities and Cl-esterase inhibitor levels in plasma samples from cancer patients and healthy individuals. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson J F, Cepelak V, Samama M M, Desnoyers P C. (eds). Edinburgh: Churchill Livingstone; 1979: 406-10.
6 Abildgaard U. A review of antithrombin III. In: The Physiological Inhibitors of Coagulation and Fibrinolysis. Collen D, Wiman B, Verstraete M. (eds). Amsterdam: Elsevier/North Holland Biomedical Press; 1979: 12-29.
7 Bagdasarian A, Lahiri B, Talamo R G, Wong P, Colman R W. Immunochemical studies of plasma kallikrein. J Clin Invest 1974; 54: 1444-50.
8 Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidised alpha-l-proteinase inhibitor and alpha-l-antichymotrypsin. J Biol Chem 1980; 255: 3991-7.
9 Bouma B N, Miles L A, Beretta G, Griffin J H. Human plasma prekallikrein. Studies of its activation by activated factor XII and its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980; 19: 1151-60.
10 Bruhn H D, Bruck M, Albert J P. Plasma prekallikrein in hypertension. Acta Chir Scand 1982; Suppl 509: 133-5.
11 Colman R W, Mason J W, Sherry S. The kallikreinogen-kallikrein system of human plasma. Assay of components and observation in disease states. Ann Int Med 1969; 71: 763-72.
12 Colman R W, Mattier L, Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest 1969; 48: 11-22.
13 Colman R W, Bagdasarian A, Talama R C, Scott C F, Seavey M, Guinaraes J A, Pierce J B, Kaplan A P. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-62.
14 Colman R W, Wong P Y. Participation of Hageman Factor pathways in human disease states. Thromb Haemostas 1977; 38: 751-75.
15 Cullman W, Kovary P M, Muller N, Dick W. Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). Clin Exp Immunol 1982; 49: 618-22.
16 Egberg N, Gallimore M J. Studies on Hageman factor, plasma prekallikrein, kallikrein like activity and kallikrein inhibition in plasma samples from normal subjects and clinical material. In: Kinins III Adv Exp Med Biol. Fritz H, Back N, Dietze G, Haberland G L. (eds). New York: Plenum; 1983: 109-17.
17 Egberg N, Gallimore M J, Green K, Jacobsson J, Vesterqvist O, Wiman B. Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostocycline metabolites. (in press).
18 Friberger P, Gallimore M J. Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma. In: Kinins I V, Part B, Greenbaum L M, Margolius H S. (eds). New York: Plenum; 1986: 543-8.
19 Führer G, Gallimore M J, Heller W, Hoffmeister H-E. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. In: Kinins I V, Greenbaum L M, Margolius H S. (eds). New York: Plenum; (in press).
20 Führer G, Heller W, Hoffmeister H-E. Effect of high and low molecular weight heparin preparations on chromogenic substrate assays for components of the kallikrein-kinin system. In: Kinins I V, Greenbaum L M, Margolius H S. (eds). New York: Plenum; (in press).
21 Gallimore M J, Fareid E, Stormorken H. The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb Res 1978; 12: 409-20.
22 Gallimore M J, Amundsen E, Larsbraaten M, Lyngaas K, Fareid E. Studies on plasma kallikrein using chromogenic peptide substrate assays. Thromb Res 1979; 16: 695-703.
23 Gallimore M J, Ford C H J, Howell A, Newman C E. Further studies on components of the plasma kallikrein system in plasma samples from cancer patients and normal individuals. In: Progress in Fibrinolysis. Davidson J F, Nilsson I M, Astedt B. (eds). Edinburgh: Churchill Livingstone; 1981: 256-8.
24 Gallimore M J, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein like activity in human plasma. Thromb Res 1982; 25: 293-8.
25 Gallimore M J, Milford AWard. Studies on components of the plasma kallikrein and complement systems in plasma and serum sample from normal individuals and patients with hereditary angioedema. In: Kinins III. Adv Exp Med Biol. Fritz H, Back N, Dietze G, Haberland G L. (eds). New York: Plenum; 1983: 1099-107.
26 Harpel P C. Human plasma alpha 2 macroglobulin. An inhibitor of plasma kallikrein. J Exp Med 1970; 132: 329-37.
27 Harpel P C. Cl inactivator inhibition by plasmin. J Clin Invest 1970; 49: 568-76.
28 Hathaway W E, Belhanson L P, Hathaway H S. Evidence for a new thromboplastin factor: case report, coagulation studies and physiochemical studies. Blood 1965; 26: 521-8.
29 Heber H, Geiger R, Heimburger N. Human plasma kallikrein. Purification, enzyme characterisation and quantitative determination in plasma. Hoppe-Seylers Z Physiol Chem 1978; 359: 649-69.
30 Heller E, Führer G, Hoberg S, Hoffmeister H-E, Philapitsch A. Effect of elevated Clesterase inhibitor levels on elastase release in vitro. A proposed model for shock. (in press).
31 Hojima Y, Tankersley D L, Miller-Andersson M, Pierce J V, Pisano J J. Enzymatic properties of human Hageman factor fragment with plasma prekallikrein and synthetic substrates. Thromb Res 1980; 18: 417-30.
32 Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
33 Kierulf P, Aasen A O, Aune S, Godai H C, Ruud T E, Vaage J. Chromogenic peptide substrates in patients with multiple trauma. Acta Chir Scand 1982; Suppl 509: 69-72.
34 KabiVitrum A B. Stockholm, Sweden. COA-SET Prekallikrein Kit..
35 Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 1978; 91: 83-96.
36 Lacombe N J. Deficit constitutional en un nouveau facteur de la coagulation intervenant au niveau de contact. Le facteur »Flaujeac«. C R Acad Sci (D) 1975; 280: 1039-41.
37 Lasson A. Acute pancreatitis in man. Scand J Gastro 1984; Suppl 99: 1-57.
38 Mandle R J, Colman R W, Kaplan A P. Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci 1976; 11: 4179-85.
39 McConnell D J, Mason B. The isolation of human plasma prekallikrein. Br J Pharmacol 1970; 38: 490-502.
40 Mullertz S. The primary plasmin inhibitor, ±₂-plasmin inhibitor or ±₂-antiplasmin : a review. In: The Physiological Inhibitors of Coagulation and Fibrinolysis. Collen D, Wiman B, Verstraete M. (eds). Amsterdam: Elsevier/North Holland Biomedical Press; 1979: 87-102.
41 Pisaro J J. Chemistry and biology of the kallikrein-kinin system. In: Proteases and Biological Control. Cold Spring Harbour. Conference on Cell Proliferation 1975; 02: 199-207.
42 Ratnoff O D, Colopy J E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 601-13.
43 Ratnoff O D, Naff G B. The conversion of Cls to Cl esterase by plasmin and trypsin. J Exp Med 1967; 125: 337-45.
44 Ratnoff O D, Pensky J, Ogston D, Naff G B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C’lr subcomponent of the first component of complement by serum C’l esterase inhibitor. J Exp Med 1969; 129: 315-24.
45 Revak S D, Cochrane C G, Griffin J H. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-75.
46 Revak S D, Cochrane C G, Griffin J H. Multiple forms of active Hageman factor (coagulation Factor XII) produced during contact activation. Fed Proc 1977; 36: 329-38.
47 Saito H, Ratnof W, Waldman A, Abraham J P. Fitzgerald trait. Deficiency of a hitherto unrecognised agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability (PF/dil). J Clin Invest 1975; 55: 1082-9.
48 Saito H, Goodnough L T, Soria J, Soria C, Aznar J, Espana F. Heterogeneity of human prekallikrein deficiency (Fletcher trait). Evidence that 5 of 18 cases are positive for cross-reacting material. N Engl J Med 1981; 305: 910-4.
49 Saugstad O D, Harvie A, Langslet A. Activation of the kallikrein-kinin system in premature infants with respiratory distress syndrome (RDS). Acta Chir Scand 1982; Suppl 509: 79-80.
50 Schrader J, Gallimore M J, Eisenhauer T, Isemer F E, Schoel G, Bruggeman M, Scheler F. Parameters of the kallikreinkinin, coagulation and fibrinolytic systems as early indicators of kidney transplant rejection. Nephron. (in press).
51 Schreiber A D, Kaplan A P, Austen K F. Inhibition by Cl INH of Hageman factor fragment activation of coagulation, fibrinolysis and kinin generation. J Clin Invest 1974; 52: 1402-9.
52 Smith-Erichsen N, Aasen A O, Amundsen E. Treatment of sepsis in the surgical patient evaluated by means of chromogenic peptide substrate assays. Acta Chir Scand 1982; Suppl 509: 33-8.
53 Stormorken H, Baklund A, Gallimore M J, Ritland S. Chromogenic substrate assay of plasma prekallikrein. Heaemostasis 1978; 07: 69-75.
54 Thompson R, Mandle Jr R, Kaplan A P. Association of Factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-84.
55 Van Vliet A C M, van Vliet H H D M, Dzolijic-Danilovic G, Wilson J H P. Plasma prekallikrein and endotoxemia in liver cirrhosis. Thromb Haemostas 1981; 45: 65-9.
56 Velasco F, Torres A, Guerrero A, Andres P, Guerro R, Aljama P, Alvarez F. Behavior of the contact phase of blood coagulation in the adult respiratory distress syndrome (ARDS). Thromb Haemostas 1986; 55: 357-60.
57 Vennerod A H, Laake K, Solberg A K, Stromland S. Inactivation and binding of human plasma kallikrein by antithrombin III and heparin. Thromb Res 1976; 09: 457-66.
58 Walker I D, Gallimore M J, Imrie C W, Davidson J F. The coagulation, fibrinolytic and plasma kallikrein systems in acute pancreatitis. In: Progress in Fibrinolysis. Davidson J F, Nilssson I M, Astedt B. (eds). Edinburgh: Churchill Livingstone; 1981: 291-3.
59 Ward P N. A plasmin split fragment of C3 as a new chemotactic factor. J Exp Med 1967; 126: 189-93.
60 Werk W. Plasma kallikrein activities, FDP and Cl-esterase inhibitor levels in breast cancer patients. In: Progress in Fibrinolysis. Davidson J F, Nilsson I M, Astedt B. (eds). Edinburgh: Churchill Livingstone; 1981: 259-63.
61 Wuepper K D. Biochemistry and biology of components of the plasma kinin forming system. In: Inflammation: Mechanisms and Control. Lepow I H, Ward P A. New York: Academic Press; 1972: 93-117.
62 Wuepper K D. Prekallikrein deficiency in man. J Exp Med 1973; 138: 1345-55 63.